Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
QuidelOrtho (Nasdaq: QDEL) released episode 55 of its Science Bytes podcast on Jan 22, 2026, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. Mullens discusses pressures on the blood supply from routine trauma and climate-driven emergencies, rising demand for O-type units due to low-titer whole blood programs, the role of automation in immunohematology, and the importance of year-round donor engagement. The episode highlights the link between donors, diagnostics, and patient care and is available on major streaming platforms and the company's website.
QuidelOrtho (Nasdaq: QDEL) will report fourth quarter and full-year 2025 financial results for the period ended December 28, 2025, after market close on Wednesday, February 11, 2026. A conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET the same day, with presentation materials and a replay available in the Events & Presentations section of the company's Investor Relations website.
Investors can join the live webcast via the IR site or by phone at 833-470-1428 (U.S.) or +1 929-526-1599 (international) using Conference ID 690468.
QuidelOrtho (Nasdaq: QDEL) released Episode 54 of its Science Bytes podcast on Dec. 18, 2025, featuring Jonathan Siegrist, PhD, EVP of Research & Development and CTO.
Key topics include high-sensitivity troponin for faster cardiac diagnosis, non-invasive gastrointestinal assays, rapid combo respiratory tests, advances in molecular platforms, informatics and AI, and R&D strategies to scale diagnostic innovation globally. The episode discusses how these technologies streamline clinical workflows and support timely patient care decisions.
The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) announced that management will participate in two investor conferences in early December 2025: the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025 with a fireside chat at 10:00 a.m. ET / 7:00 a.m. PT, and the Citi Global Healthcare Conference on December 3, 2025 with a fireside chat at 1:00 p.m. ET / 10:00 a.m. PT.
Investors can access the live webcasts and replays in the Events & Presentations section of QuidelOrtho's Investor Relations site at https://ir.quidelortho.com/.
QuidelOrtho (Nasdaq: QDEL) released Episode 53 of its Science Bytes podcast on Nov 20, 2025, featuring Dr. Qian Ding discussing early detection of diabetes.
Key points: early testing can change patient trajectories; emerging biomarkers (C-peptide, pro‑insulin, adiponectin) add metabolic insight beyond glucose; automation-ready lab platforms speed reliable results; early detection supports value-based care and may reduce costly interventions; tailored testing promotes equity across populations. The episode is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) launched the QUICKVUE Influenza + SARS Test, a CLIA‑waived, 510(k)‑cleared rapid immunoassay for professional use that detects and differentiates influenza A, influenza B and SARS‑CoV‑2 antigens from a single nasal swab.
The visually read combo test delivers results in as fast as 10 minutes, is designed for physician office labs, urgent care, emergency departments, pharmacies and decentralized hospital labs, and complements QuidelOrtho's instrumented SOFIA 2 Flu + SARS product as a cost‑effective point‑of‑care option. The test is available in the United States through existing distribution channels and is not intended for in‑home use.
QuidelOrtho (Nasdaq: QDEL) reported Q3 2025 total revenue of $700 million and an adjusted diluted EPS of $0.80. GAAP results included a $701 million non-cash goodwill impairmentGAAP net loss of $733 million and GAAP diluted loss per share of $10.78. Adjusted EBITDA was $177 million with a 25% margin. The company completed a debt refinancing to improve financial flexibility and narrowed full-year 2025 guidance to $2.68–$2.74 billion revenue, $585–$605 million adjusted EBITDA, and $2.00–$2.15 adjusted diluted EPS. Q3 results reflected a 63% decline in COVID-19 revenue and continued wind-down of the U.S. Donor Screening portfolio.
QuidelOrtho (Nasdaq: QDEL) announced FDA 510(k) clearance for the VITROS hs Troponin I Assay on November 3, 2025.
The assay measures cardiac troponin I in human plasma (heparin) to aid diagnosis of myocardial infarction and integrates with existing VITROS Systems and workflows. The company said U.S. commercial rollout for laboratories running VITROS Systems will begin later this year. QuidelOrtho highlighted studies showing hs troponin pathways can reduce 30-day mortality by 12% and 1-year mortality by 10% in suspected acute coronary syndrome patients.
QuidelOrtho (Nasdaq: QDEL) released Episode 52 of its Science Bytes podcast on October 23, 2025, titled "The Power of Informatics in Clinical Decision-Making." The episode features George Wierschem, Senior Global Product Manager – Informatics, who draws on over 30 years of laboratory experience to explain how informatics platforms connect instruments, data systems and clinical decisions.
Key takeaways include:
- Instant insight: turning data into decisions
- Smarter workflows: automation reduces errors and speeds results
- Point-of-care confidence: quality across decentralized testing
- Built-in security: cyber-safe systems without slowing operations
- Trustworthy data: full tracking and accountability
The episode highlights informatics' role in improving lab efficiency, data integrity and patient care. The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) will report its Third Quarter 2025 financial results for the period ended September 28, 2025 after market close on Wednesday, November 5, 2025.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results, with presentation materials posted to the Events & Presentations section of the investor relations website at the time of the call.
Live access: webcast via https://ir.quidelortho.com; phone dial-in: 833-470-1428 (US) or +1 929-526-1599 (international) using Conference ID 415850. A replay will be available on the investor relations site shortly after the event.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
